Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWP42003 (cannabidiol) as adjunctive therapy in first-line treatment of schizophrenia
2013-000212-22Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia and Schizophrenia Spectrum Disorders (SSD) comparing GWP42003 (cannabidiol) adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change in PANSS Total score. Started Oct 2013; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2013-000212-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000212-22.